Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pharvaris N.V. - Ordinary Shares (NQ:PHVS)

25.71 -0.22 (-0.85%)
Streaming Delayed Price Updated: 10:13 AM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pharvaris N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
Antagonism of the bradykinin B2 receptor via treatment with deucrictibant resulted in statistically significant reduction in rate of HAE attacks 
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Extraordinary Meeting of Shareholders
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Present at the WSAAI Annual Meeting 2024
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Analyst Expectations for Pharvaris's Future ↗
 
Via Benzinga
News headline image
Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision ↗
The company is working on a treatment for swelling attacks associated with a genetic disease. 
Via Investor's Business Daily
News headline image
FDA Clears Pharvaris' Trial For Investigational Drug For Swollen Blood Vessels, Stock Jumps ↗
Pharvaris receives FDA approval to advance deucrictibant for hereditary angioedema prophylaxis, lifting clinical hold. Learn about the latest developments in HAE treatment. 
Via Benzinga
News headline image
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Gold Moves Higher; Campbell Soup Earnings Top Expectations ↗
U.S. stocks traded mixed toward the end of trading on Wednesday. The Dow traded up 0.05% to 36,143.40 while the NASDAQ fell 0.06% to 14,221.51. The S&P 500 also fell, dropping, 0.05% to 4,564.73. 
Via Benzinga
Topics Stocks
News headline image
Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second-quarter results. 
Via Benzinga
News headline image
Turnaround For Pharvaris Since FDA Clinical Hold - Data Shows Its Oral Hereditary Angioedema Treatment Cuts Attacks ↗
Pharvaris NV (NASDAQ: PHVS) released topline data from the CHAPTER-1 Phase 2 study meeting its primary endpoint, with deucrictibant demonstrating statistically significant and clinically meaningful... 
Via Benzinga
News headline image
Crude Oil Down 4%; Pharvaris Shares Spike Higher ↗
U.S. stocks traded mostly flat midway through trading, with the S&P 500 turning lower on Wednesday. The Dow traded up 0.01% to 36,126.75 while the NASDAQ rose 0.03% to 14,233.77. The S&P 500 also fell,... 
Via Benzinga
Topics Stocks
News headline image
AMD Stock Alert: What to Expect From Advanced Micro Devices ‘Advancing AI’ Event ↗
Advanced Micro Devices stock is climbing higher on Wednesday as AMD investors prepare for the company's Advancing AI event today. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
THOR Industries Reports Upbeat Earnings, Joins Dave & Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded higher, with the Dow Jones index gaining more than 50 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
Shopify (SHOP) Stock Falls Following Analyst Downgrade ↗
Shopify stock is taking a beating on Wednesday after shares of SHOP were hit with a downgrade from Wedbush analyst Scott Devitt. 
Via InvestorPlace
News headline image
Why Is Pharvaris (PHVS) Stock Up 36% Today? ↗
Pharvaris stock is rising higher on Wednesday following news of an underwritten offering for PHVS shares and pre-funded warrants. 
Via InvestorPlace
News headline image
US Stocks Higher; Private Payrolls Rise By 103,000 In November ↗
U.S. stocks traded higher this morning, following the release of economic reports on Wednesday. Following the market opening Wednesday, the Dow traded up 0.21% to 36,200.86 while the NASDAQ rose 0.28%... 
Via Benzinga
Topics Stocks
News headline image
Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris to Present at the GA²LEN UCARE Conference 2023
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris To Present at the APAAACI 2023 International Conference
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris To Present at the CIIC Fall 2023 Conference
From Pharvaris N.V.
Via GlobeNewswire
News headline image
Pharvaris' Promising Oral Treatment Solutions For Treating Swollen Blood Vessels - Analyst Sees 35% Upside ↗
Wedbush has initiated coverage on Pharvaris N.V. (NASDAQ: PHVS), noting that the company stands out as one of the players with their strategy to develop and advance oral therapeutic options in both the... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023 ↗
 
Via Benzinga
News headline image
Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference
From Pharvaris N.V.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.